Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases最新文献

筛选
英文 中文
Bilateral Delayed Injection-site Reactions to Ixekizumab. Ixekizumab的双侧延迟注射部位反应。
IF 1.8
Jobson Lopes de Oliveira, Guilherme Ferreira Maciel da Silva
{"title":"Bilateral Delayed Injection-site Reactions to Ixekizumab.","authors":"Jobson Lopes de Oliveira, Guilherme Ferreira Maciel da Silva","doi":"10.1097/RHU.0000000000002415","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002415","url":null,"abstract":"","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telemedicine in Rheumatology in the United States: A Scoping Review of Modalities, Outcomes, and Costs in Support of a Hybrid Model of Care. 美国风湿病远程医疗:支持混合护理模式的模式、结果和成本的范围审查。
IF 1.8
Maria F Carpintero, Marco A Ladino
{"title":"Telemedicine in Rheumatology in the United States: A Scoping Review of Modalities, Outcomes, and Costs in Support of a Hybrid Model of Care.","authors":"Maria F Carpintero, Marco A Ladino","doi":"10.1097/RHU.0000000000002412","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002412","url":null,"abstract":"<p><strong>Background: </strong>Shortages and geographic maldistribution of rheumatologists limit access to rheumatology care in the United States. Tele-rheumatology grew from targeted rural and Veterans Affairs programs into mainstream practice during the coronavirus disease 2019 pandemic, and its postpandemic role remains unsettled.</p><p><strong>Objective: </strong>To map the modalities, settings, and reported outcomes of telemedicine in US rheumatology.</p><p><strong>Design: </strong>Scoping review following Joanna Briggs Institute methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (Supplemental Digital Content 1, https://links.lww.com/RHU/A996) reporting.</p><p><strong>Setting: </strong>MEDLINE/PubMed, the Cochrane Library, and Scopus were searched.</p><p><strong>Participants: </strong>Sixty US reports from 48 programs involving adults and children with rheumatic diseases, caregivers, and rheumatology clinicians.</p><p><strong>Intervention: </strong>Video and telephone visits, clinic-to-clinic telemedicine, electronic consultation (eConsult), remote monitoring, and hybrid care.</p><p><strong>Main outcome measures: </strong>Access, clinical effectiveness, patient and clinician experience, cost, safety, and equity.</p><p><strong>Results: </strong>Telemedicine reduced travel and patient-borne costs, improved appointment completion, and shortened the path to specialist input through eConsult triage. Disease activity was comparable to in-person care in established patients, and structured telephone and e-visit programs improved gout treatment targets. In the largest randomized trial, satisfaction and medication toxicity monitoring were lower with telemedicine; remote joint assessment remained unreliable; and uptake was lower among older, non-English-speaking, Black, and low-income patients. Health-system savings are unproven.</p><p><strong>Limitation: </strong>Predominantly observational, pandemic-influenced evidence.</p><p><strong>Conclusion: </strong>Telemedicine complements rather than replaces in-person rheumatology care. A hybrid model anchored by face-to-face evaluation, with structured visit selection and safety monitoring, should be tested in pragmatic trials with full economic and equity evaluation.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149280771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutropenia and Splenomegaly in Rheumatoid Arthritis: Felty Syndrome. 类风湿关节炎中性粒细胞减少和脾肿大:Felty综合征。
IF 1.8
Yi-Fan Mai, Tzu-Hao Li
{"title":"Neutropenia and Splenomegaly in Rheumatoid Arthritis: Felty Syndrome.","authors":"Yi-Fan Mai, Tzu-Hao Li","doi":"10.1097/RHU.0000000000002413","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002413","url":null,"abstract":"","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149291735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concomitant Fibromyalgia in Patients With Other Rheumatic Diseases: Pain Level and Treatment Response. 其他风湿病患者伴发纤维肌痛:疼痛水平和治疗反应。
IF 1.8
Robert S Katz, Ben J Small, Jessica Polyak, Neil Manadan, Seth Adler, Gianna Elias, Dahlia Chavez, Julia Worden
{"title":"Concomitant Fibromyalgia in Patients With Other Rheumatic Diseases: Pain Level and Treatment Response.","authors":"Robert S Katz, Ben J Small, Jessica Polyak, Neil Manadan, Seth Adler, Gianna Elias, Dahlia Chavez, Julia Worden","doi":"10.1097/RHU.0000000000002404","DOIUrl":"10.1097/RHU.0000000000002404","url":null,"abstract":"<p><strong>Introduction: </strong>Fibromyalgia commonly coexists with rheumatic diseases and may complicate disease assessment and management. This study evaluated whether patients with rheumatic diseases and concomitant fibromyalgia differed in pain severity and patient-perceived treatment response compared with those without fibromyalgia.</p><p><strong>Methods: </strong>Four patient groups were evaluated in a historical, cross-sectional study: (1) fibromyalgia alone, diagnosed using the 2016 American College of Rheumatology criteria; (2) another rheumatic disease and concomitant fibromyalgia, requiring a fibromyalgia Polysymptomatic Distress Scale (PDS) score of >11 points; (3) another rheumatic disease and a PDS score of 10 or 11 indicating \"borderline\" fibromyalgia; (4) a control group consisting of patients with nonfibromyalgia rheumatic disease and a PDS score <10. Pain level (0=no pain, 10=worst pain possible) and treatment response (0=no response, 10=positive response) were assessed with visual analog scales.</p><p><strong>Results: </strong>Among 503 patients, 108 were diagnosed with fibromyalgia alone; 83 with concomitant FMS; 39 with borderline FMS; and 273 with nonfibromyalgia rheumatic disease. The worst pain was reported by patients with concomitant fibromyalgia (mean, 6.7), followed by those with fibromyalgia alone (6.3) and borderline concomitant fibromyalgia (6.2). Nonfibromyalgia patients reported a pain level of 4. Patients with fibromyalgia alone, concomitant fibromyalgia, and borderline concomitant fibromyalgia reported worse response to treatment (6.4, 7.1, and 7.8) than nonfibromyalgia patients (8.3).</p><p><strong>Conclusion: </strong>These findings underscore the pain burden and difficulty in treating patients with inflammatory rheumatic diseases and concomitant fibromyalgia. Recognizing fibromyalgia in patients with other rheumatic diseases is important to tailor more effective pain management strategies, improve treatment outcomes, and distinguish symptoms related to fibromyalgia from those of the underlying rheumatic disease.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Evidence of Anifrolumab Use in Mexican Patients With Systemic Lupus Erythematosus: A Multicenter Observational Study. 在墨西哥系统性红斑狼疮患者中使用Anifrolumab的真实证据:一项多中心观察性研究。
IF 1.8
Ángel Alejandro Castillo Ortiz, Wallace Rafael Arturo Muñoz Castañeda, Luis Francisco Valdés Corona, Javier Merayo-Chalico, Antonio González Pineda, Diana Gabriela Valencia Reséndiz, David Omar Sánchez Herrera
{"title":"Real-world Evidence of Anifrolumab Use in Mexican Patients With Systemic Lupus Erythematosus: A Multicenter Observational Study.","authors":"Ángel Alejandro Castillo Ortiz, Wallace Rafael Arturo Muñoz Castañeda, Luis Francisco Valdés Corona, Javier Merayo-Chalico, Antonio González Pineda, Diana Gabriela Valencia Reséndiz, David Omar Sánchez Herrera","doi":"10.1097/RHU.0000000000002409","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002409","url":null,"abstract":"<p><strong>Background: </strong>Anifrolumab is a monoclonal antibody directed against type I interferon receptor subunit 1 (IFNAR1) that blocks the interferon signaling pathway associated with key inflammatory processes involved in the pathogenesis of systemic lupus erythematosus (SLE). Its specific use in the Mexican population has not been previously evaluated; therefore, this study aimed to assess the impact of anifrolumab therapy on corticosteroid use in Mexican patients with moderate-to-severe SLE.</p><p><strong>Methods: </strong>A multicenter, observational medical record review study was conducted from September 2024 to May 2025, including Mexican patients with moderate-to-severe SLE who received anifrolumab for 6 months. The primary outcomes were disease control and remission, as defined by the LLDAS and DORIS criteria, respectively. Secondary outcomes included changes in prednisone use and immunologic (anti-dsDNA and complement levels C3 and C4) and hematological parameters.</p><p><strong>Results: </strong>Seventeen patients were included in the study. At the start of treatment, the average prednisone dose was 23.0±18.0 mg, which was significantly reduced by the third month to 5.0±3.0 mg (p=0.001) and further reduced to 2.5±2.5 mg (p<0.001) by the 6th month. Approximately 41% of patients stopped using prednisone by month 6 of treatment. A total of 62.5% of patients achieved LLDAS by the 3rd month (p=0.008), while 43.8% reached clinical remission through DORIS criteria (p=0.023), and 37.5% reached complete remission (p=0.041) by the 6th month of treatment.</p><p><strong>Conclusions: </strong>Treatment with anifrolumab for 6 months significantly reduced SLE activity, improved immunologic parameters, and reduced corticosteroid use, as reflected by the achievement of therapeutic goals such as LLDAS and DORIS.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Relationship Between Pan Immune-Inflammation Value and Disease Activity in Ankylosing Spondylitis. 强直性脊柱炎泛免疫炎症值与疾病活动性的关系。
IF 1.8
Ismail Sayinbatur, Nuh Atas, Aski Vural
{"title":"The Relationship Between Pan Immune-Inflammation Value and Disease Activity in Ankylosing Spondylitis.","authors":"Ismail Sayinbatur, Nuh Atas, Aski Vural","doi":"10.1097/RHU.0000000000002410","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002410","url":null,"abstract":"<p><strong>Objectives: </strong>Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting the axial skeleton and peripheral joints, causing pain, stiffness, and reduced function. Monitoring disease activity is crucial, but no specific laboratory markers reflect disease activity in AS. This study evaluated the relationship between pan immune-inflammation value (PIIV) and disease activity in AS.</p><p><strong>Materials and methods: </strong>This study included patients with AS fulfilling the modified New York classification criteria. Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP). Data included demographic, clinical, treatment, and laboratory variables, including C-reactive protein (CRP), erythrocyte sedimentation rate, blood counts, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio, systemic immune-inflammation index (SII), and PIIV.</p><p><strong>Results: </strong>Of 64 patients (female/male: 22/42), 38 (59.4%) had active disease according to BASDAI. The active group showed higher PIIV, ASDAS-CRP, platelet count, PLR, and SII, and lower hemoglobin than the inactive group. PIIV correlated with BASDAI, ASDAS-CRP, and inflammatory markers including CRP, erythrocyte sedimentation rate, neutrophil, platelet, and monocyte counts, neutrophil-to-lymphocyte ratio, PLR, monocyte-to-lymphocyte ratio, and SII.</p><p><strong>Conclusion: </strong>PIIV was significantly higher in active AS and correlated with disease activity and inflammatory markers. It may support disease activity assessment in AS.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of Large Language Models in Answering Juvenile Systemic Lupus Erythematosus Questions: A Blinded Expert-based Comparative Study. 大型语言模型在回答青少年系统性红斑狼疮问题中的表现:一项基于专家的盲法比较研究。
IF 1.8
Ufuk Furkan Ozdemir, Serpil Meric Toprak, Aybuke Gunalp, Esma Aslan, Mehmet Yildiz, Oya Koker, Amra Adrovic, Sezgin Sahin, Kenan Barut, Fatih Haslak, Kubra Ozturk, Ozgur Kasapcopur
{"title":"Performance of Large Language Models in Answering Juvenile Systemic Lupus Erythematosus Questions: A Blinded Expert-based Comparative Study.","authors":"Ufuk Furkan Ozdemir, Serpil Meric Toprak, Aybuke Gunalp, Esma Aslan, Mehmet Yildiz, Oya Koker, Amra Adrovic, Sezgin Sahin, Kenan Barut, Fatih Haslak, Kubra Ozturk, Ozgur Kasapcopur","doi":"10.1097/RHU.0000000000002411","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002411","url":null,"abstract":"<p><strong>Background: </strong>Large language models are increasingly used to obtain medical information, but their performance in juvenile systemic lupus erythematosus remains insufficiently characterized.</p><p><strong>Objective: </strong>To compare expert-rated response quality and clinical relevance across 4 artificial intelligence (AI) models using standardized juvenile systemic lupus erythematosus-related questions.</p><p><strong>Design: </strong>Cross-sectional expert-based comparative study.</p><p><strong>Setting: </strong>Freely accessible consumer-facing web interfaces evaluated on December 30, 2025.</p><p><strong>Participants: </strong>Ten pediatric rheumatology experts.</p><p><strong>Intervention: </strong>Not applicable.</p><p><strong>Main outcome measures: </strong>Twenty standardized questions generated 80 AI responses, rated on a 5-point Likert Scale. Model performance was compared using the Friedman test with Kendall W and Bonferroni-corrected post hoc analyses; interrater agreement was assessed using intraclass correlation coefficients (ICCs).</p><p><strong>Results: </strong>DeepSeek achieved the highest median rating [5 (1 to 5)], followed by Gemini [4 (2 to 5)], ChatGPT [4 (3 to 5)], and Copilot [4 (3 to 5)]. Overall expert-rated performance differed significantly among models [Friedman χ2(3) = 63.553, p < 0.001; Kendall W = 0.106]. DeepSeek outperformed ChatGPT, Gemini, and Copilot (all p < 0.001), while Gemini performed better than ChatGPT (p = 0.007) and Copilot (p < 0.001). Interrater agreement was highest for DeepSeek (ICC =0 .734) and lowest for Copilot (ICC = 0.043). Trust scores remained unchanged before and after evaluation [4 (3 to 5) vs. 4 (3 to 5), p=0.414].</p><p><strong>Limitation: </strong>Single-time-point, single-response testing did not assess within-model reproducibility, and the question set was not formally validated.</p><p><strong>Conclusion: </strong>AI models differed in expert-rated performance and interrater agreement; outputs should be interpreted cautiously and with specialist oversight.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149140233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced Lumbar Lordosis in Fibromyalgia: Radiographic Evidence of Lumbar Straightening by L1-L5 Cobb Angle. 纤维肌痛症腰椎前凸减轻:L1-L5 Cobb角腰椎矫直的影像学证据。
IF 1.8
Robert S Katz, Tony Farkash, Seth Adler, Julia Worden, Dahlia Chavez, Ben Small
{"title":"Reduced Lumbar Lordosis in Fibromyalgia: Radiographic Evidence of Lumbar Straightening by L1-L5 Cobb Angle.","authors":"Robert S Katz, Tony Farkash, Seth Adler, Julia Worden, Dahlia Chavez, Ben Small","doi":"10.1097/RHU.0000000000002406","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002406","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Reduced lumbar lordosis has been observed in patients with low back pain, but lumbar straightening has not been well characterized in fibromyalgia. We hypothesized that fibromyalgia would be associated with reduced lumbar curvature on standing radiographs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate lumbar lordosis, quantified by the L1-L5 Cobb angle, in patients with fibromyalgia compared with patients with other rheumatic diseases and low back pain.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Retrospective, cross-sectional observational study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Rheumatology office practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;A consecutive series of 245 patients aged 18 to 70 years who underwent lumbar spine radiography for moderate-to-severe low back pain between 2012 and 2014 was reviewed. Of these, 164 patients met American College of Rheumatology criteria for fibromyalgia and 81 met criteria for another rheumatic disease, including rheumatoid arthritis, osteoarthritis, or polymyalgia rheumatica.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Not applicable.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcome measures: &lt;/strong&gt;Lumbar lordosis was measured on standing lateral lumbar spine radiographs using the Cobb angle between the superior endplate of L1 and inferior endplate of L5. The prevalence of a nearly straight lumbar spine, defined as a Cobb angle ≤10 degrees, and more complete straightening, defined as a Cobb angle ≤5 degrees, was also assessed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Mean L1-L5 Cobb angle was significantly lower in patients with fibromyalgia than in rheumatic disease controls (15.2±12.2 degrees vs. 23.3±13.4 degrees, respectively; p &lt;0.001). A Cobb angle ≤10 degrees was present in 72 (44%) patients with fibromyalgia compared with 17 (21%) controls (p &lt;0.001). A Cobb angle ≤5 degrees was present in 42 (26%) patients with fibromyalgia compared with 5 (6%) controls (p &lt;0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;The study was retrospective and conducted at a single site. Both groups consisted of patients referred for lumbar imaging because of low back pain, and no asymptomatic healthy control group was included. Potential confounding factors, including body mass index, age, sex, pain duration, and medication use, were not formally analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Patients with fibromyalgia had significantly reduced lumbar lordosis and a higher prevalence of near-complete lumbar straightening than patients with other rheumatic diseases referred for lumbar imaging due to low back pain. Because lumbar straightening was also present in the comparator group, it is not specific enough to serve as a standalone diagnostic sign. Lumbar lordotic straightening may represent an additional radiographic observation associated with fibromyalgia and warrants prospective investigation, including evaluation of its potential relationship with paraspinal muscle tension.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Primary funding source: &lt;/strong&gt;This research ","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cycling Versus Swapping After First-Line TNF Inhibitor Failure in Psoriatic Arthritis: Real-World Insights From the Argentine RECCAPSO Registry. 银屑病关节炎一线TNF抑制剂失效后的循环与交换:来自阿根廷RECCAPSO注册的真实世界见解
IF 1.8
Leila Abbas, Rodrigo García-Salinas, Maximiliano Fenucci, Sebastián Magri, Marcelo Abdala, Brian Abdala, Gustavo A Medina
{"title":"Cycling Versus Swapping After First-Line TNF Inhibitor Failure in Psoriatic Arthritis: Real-World Insights From the Argentine RECCAPSO Registry.","authors":"Leila Abbas, Rodrigo García-Salinas, Maximiliano Fenucci, Sebastián Magri, Marcelo Abdala, Brian Abdala, Gustavo A Medina","doi":"10.1097/RHU.0000000000002408","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002408","url":null,"abstract":"<p><strong>Objectives: </strong>Cycling within the same mechanism of action (MoA) or swapping to a different MoA are 2 strategies after failure of advanced therapy in psoriatic arthritis (PsA). We described the frequency, clinical characteristics, and treatment trajectory of cycling versus swapping at the first switch in a multicenter Argentine PsA cohort.</p><p><strong>Methods: </strong>Retrospective cohort analysis of 350 consecutive adults with PsA fulfilling CASPAR criteria and enrolled in the RECCAPSO registry. Among 179 patients with documented first-line treatment lineage, the comparative analysis was restricted to those who discontinued first-line TNFi because of primary inefficacy or secondary loss of response. Cycling was defined as switching to another TNFi and swapping as switching to a different MoA. Between-group comparisons were exploratory and performed using Mann-Whitney U and Fisher exact tests.</p><p><strong>Results: </strong>Of 350 patients, 183 (52%) received advanced therapy; 60/179 (33.5%) experienced first-line failure, all while receiving TNFi. Of these, 18 (30%) cycled and 42 (70%) swapped. The median interval from first-line to second-line initiation was 18 months [interquartile range (IQR): 4 to 60] in cyclers and 19 months (IQR: 6 to 56) in swappers. At the first switch, swappers had higher C-reactive protein (3.4 vs. 1.6 mg/L; P=0.04) and numerically less enthesitis (38.1% vs. 66.7%; P=0.08). At the subsequent cross-sectional assessment during second-line therapy, DAPSA remission was observed in 18.4% of swappers and 0% of cyclers (P=0.09). Third-line therapy was initiated in 77.8% of cyclers and 31.0% of swappers (P=0.0015); among those reaching a third line, the median interval from second-line to third-line initiation was 5 months (IQR: 2 to 9) and 13 months (IQR: 4 to 34), respectively.</p><p><strong>Conclusions: </strong>Swapping was the predominant strategy after first-line TNFi failure. Cyclers more frequently initiated a third line and, among those who escalated, did so earlier.</p>","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response By Manadan et al to Letter Regarding Article "In-Hospital Mortality After Coronary Artery Bypass Graft Surgery With and Without Systemic Lupus Erythematosus". Manadan等人对文章“伴有和不伴有系统性红斑狼疮的冠状动脉搭桥手术后住院死亡率”的回复。
IF 1.8
Jay Manadan, Burak Celik, Ehizogie Edigin
{"title":"Response By Manadan et al to Letter Regarding Article \"In-Hospital Mortality After Coronary Artery Bypass Graft Surgery With and Without Systemic Lupus Erythematosus\".","authors":"Jay Manadan, Burak Celik, Ehizogie Edigin","doi":"10.1097/RHU.0000000000002407","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002407","url":null,"abstract":"","PeriodicalId":520664,"journal":{"name":"Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书